Memphasys Trials RoXsta™ Mega Cell: 96 Samples Processed in Under an Hour
Memphasys Limited has successfully trialed its RoXsta™ Mega Cell High-Throughput Assay, capable of processing 96 antioxidant tests in under an hour, promising a leap forward in rapid, cost-effective oxidative stress analysis.
- RoXsta™ Mega Cell processes 96 samples in less than an hour
- Significant reduction in testing time from 16 hours to 3 minutes per result
- Pilot studies include oxidative stress in cattle and professional footballers
- Potential to disrupt current laboratory antioxidant testing methods
- Partnership with Design + Industry Pty Ltd for device development
A New Era in Antioxidant Testing
Memphasys Limited (ASX: MEM), a biotechnology company known for its innovations in reproductive and diagnostic technologies, has announced a successful pilot trial of its RoXsta™ Mega Cell High-Throughput Assay device. This breakthrough technology dramatically accelerates the testing of reactive oxygen species (ROS) and antioxidant levels in biological fluids, a key metric in assessing oxidative stress.
The RoXsta™ Mega Cell device can simultaneously process 96 samples in under an hour, a stark contrast to traditional methods that can take up to 16 hours for a single result. Even more striking is the device’s ability to deliver results in as little as three minutes, positioning it as a game-changer for both commercial and research laboratories.
Pilot Studies Demonstrate Broad Applicability
Memphasys has already tested the device in diverse settings, including oxidative stress assessments in cattle and professional athletes. In a study involving professional footballers, the RoXsta™ Mega Cell not only expedited testing but also reduced costs significantly compared to conventional assay kits, which are limited in sample throughput and priced around A$300 each.
These pilot trials underscore the device’s potential to streamline antioxidant testing workflows, enabling rapid, accurate data collection that can inform targeted antioxidant therapies. The ability to quickly identify individuals who may benefit from such treatments could have far-reaching implications in both human and veterinary medicine.
Commercial Prospects and Next Steps
Developed in collaboration with product design consultancy Design + Industry Pty Ltd, the RoXsta™ Mega Cell High-Throughput Assay represents a significant commercial opportunity for Memphasys. CEO Dr David Ali highlighted the scalability of the technology and its readiness for broader deployment, signaling a shift from smaller-scale assessments to large-scale commercial applications.
As Memphasys moves into the next phase of development, the focus will likely be on optimising the assay for diverse laboratory environments and expanding its market reach. The device’s speed, accuracy, and cost-efficiency could disrupt existing laboratory practices and open new revenue streams for the company.
While the pilot results are promising, wider adoption will depend on further validation, regulatory approvals, and integration into existing diagnostic workflows. Nevertheless, the RoXsta™ Mega Cell’s performance to date positions Memphasys as a notable innovator in the oxidative stress testing space.
Bottom Line?
Memphasys’s RoXsta™ Mega Cell could redefine antioxidant testing speed and cost, setting the stage for rapid commercial expansion.
Questions in the middle?
- How will Memphasys navigate regulatory approvals for large-scale commercial use?
- What partnerships or collaborations might accelerate market adoption of the RoXsta™ Mega Cell?
- Can the device’s performance be replicated across diverse biological sample types and clinical settings?